Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
東京、日本－2022年5月26日 – 製薬業界における戦略策定や事業性評価に不可欠な信頼性の高いマーケット情報及び分析を提供するEvaluate（エバリュエート本社：ロンドン）は、2022年4月に発行した希少疾病用医薬品動向レポート 「オーファンドラッグ 2022 レポート」（原文：英語）の日本語版をリリースしました。
London, UK and Boston, MA – 11 May 2022 – Evaluate, a leading provider of market intelligence and predictive analytics for the pharmaceutical industry, has today…
United under Norstella, each brand’s key solutions and expertise will help life-sciences-focused companies get answers—not just insights—from pipeline to patient
EP Vantage Releases Half-Year Reviews of Pharma & Biotech and Medtech Performance.
Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement.
New Case Studies Highlight Niche Patient Population Identification and Analysis for Enhanced Portfolio Decision-making Using Evaluate’s Epi Analyzer
Fall comes as average cost of developing new drugs totals $4bn over the last 10 years.
Annual Pharma & Biotech World Preview Report to Launch at Bio 2017
Annual "EvaluatePharma Orphan Drug 2017 Report" sees continued growth (CAGR 2017 to 2022: +11.1%) for orphan drugs, approximately double overall prescription…
Falling stock markets, political uncertainty and continued global economic weakness all contributed to a mixed first half for the pharma and medtech industries.
Life science market intelligence firm, Evaluate Ltd today announces that it has been selected as one of 10 companies in the “Ones to Recognise” category in the Sunday…
Welcome to our press release archive. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at firstname.lastname@example.org.